LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Aug 4, 2020 → Jul 14, 2023

About LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814

LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814 is a phase 3 stage product being developed by Eli Lilly for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04501978. Target conditions include Covid19.

What happened to similar drugs?

4 of 15 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (8)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04501978Phase 3Completed

Competing Products

20 competing products in Covid19

See all competitors